Tissue-specific tumor suppressor effects of p53
p53 的组织特异性肿瘤抑制作用
基本信息
- 批准号:9112967
- 负责人:
- 金额:$ 41.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-17 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAmino AcidsAnemiaAtaxiaBasic Amino AcidsBone MarrowC-terminalDNA DamageDataDevelopmentDiseaseEmbryoEmployee StrikesFibroblastsGFI1 geneGFI1B geneGene ExpressionGene TargetingGenesGerm LinesGoalsHealthHematopoietic stem cellsHistonesHomeostasisHumanKnowledgeMalignant NeoplasmsMediatingMindMolecularMusMutationOutcomePancytopeniaPhenotypePlayProtein p53ProteinsResearchRoleSignal TransductionSpecificityTP53 geneTailTherapeutic IndexTissuesTranscriptional RegulationTumor SuppressionTumor Suppressor ProteinsUrsidae Familybasediagnosis designgranule cellimprovedin vivoinsightleukemiamedulloblastomamouse modelneoplastic cellnew therapeutic targetnovelnovel strategiesprotein protein interactionrecombinaseresponsetargeted treatmenttranscription factortumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The tumor suppressor p53 has been implicated as playing a key role in human cancer. p53 exerts much of its activity as a transcription factor that regulates gene expression that contributes to the suppression of tumor formation. Its C-terminus bears remarkable similarity to that of histone tails. Both are highly enriched in basic amino acids
and both are extensively post-translationally modified. Like histone tails, the C-terminus of p53 can be considered a protein-protein interaction module. This in turn regulates its activity as a transcription factor. To address the role of the C-terminus of p53 in its activity, a targeted mutation was made in the mouse that leads to endogenous expression of a truncated form of p53 that lacks the C-terminal 24 amino acids. When p53∆CTD is expressed in the germ-line, mice show two overt phenotypes: a reduced number of hematopoietic stem cells leading to severe anemia and impaired proliferation of granule cells resulting in defective cerebellar development and ataxia. The underlying molecular basis involves tissue-specific alterations in p53 target gene selection and expression. The striking tissue specificity of these phenotypes was unexpected and quite intriguing. In addition, study of the Trp53∆CTD/∆CTD mice has led to the identification of novel, tissue-specific p53 target genes. Given that p53 has such potent tumor suppressor activity, it is intriguing to speculate that this might be exploited as a rational
basis for targeted therapy. However, the apparently ubiquitous expression of p53 suggests that it would be difficult to achieve an effective therapeutic index. Findings with Trp53∆CTD/∆CTD mice demonstrate that the C-terminal domain of p53 exerts tissue- specific effects in a target gene-selective manner. It is thus proposed that interfering with the function of the C- terminal domain of p53 can be utilized for targeted therapy that is highly tumor-specific. With that long-term goal in mind, three specific aims are proposed. The first is to elucidate the molecular basis for the C-terminal domain in p53-mediated bone marrow failure. Second is to determine the role of the p53 C-terminal domain in cerebellar granule cell homeostasis and tumorigenesis. Finally, is to gain molecular insight into how the p53 C- terminal domain regulates activated p53 signaling. As the C-terminus has been well characterized as a protein- protein interaction module, it is proposed that inhibiting the protein interactions of the C-terminus represents a novel targeted therapy in specific tumor types. Thus, the long-term goal of these studies is to use in vivo mouse models to gain novel insights into the role of p53 in leukemia and medulloblastoma, as well as to provide new approaches for targeted therapies in these diseases.
描述(由申请人提供):肿瘤抑制因子 p53 被认为在人类癌症中发挥着关键作用,p53 发挥其作为调节基因表达的转录因子的活性,从而有助于抑制其 C 末端的形成。与组蛋白尾部具有显着的相似性,两者都富含碱性氨基酸。
与组蛋白尾巴一样,p53 的 C 末端可被视为蛋白质-蛋白质相互作用模块,这反过来又调节其作为转录因子的活性。当 p53ΔCTD 为 p53 活性时,在小鼠中进行了靶向突变,导致缺乏 C 端 24 个氨基酸的截短形式的 p53 的内源表达。在种系中表达,小鼠表现出两种明显的表型:造血干细胞数量减少导致严重贫血,颗粒细胞增殖受损导致小脑发育缺陷和共济失调,其潜在的分子基础涉及 p53 靶标的组织特异性改变。这些表型的显着组织特异性是出乎意料且非常有趣的,对 Trp53ΔCTD/ΔCTD 小鼠的研究导致了新的、鉴于 p53 具有如此强大的肿瘤抑制活性,有趣的是推测这可能被用作一种合理的方法。
然而,p53 明显普遍的表达表明,Trp53ΔCTD/ΔCTD 小鼠的研究结果表明,p53 的 C 末端结构域在体内发挥组织特异性作用。因此提出干扰p53 C末端结构域的功能可用于高度肿瘤特异性的靶向治疗。考虑到长期目标,提出了三个具体目标,第一个是阐明 p53 介导的骨髓衰竭中 C 端结构域的分子基础,第二个是确定 p53 C 端结构域在小脑中的作用。最后,是从分子角度了解 p53 C 末端结构域如何调节激活的 p53 信号传导,因为 C 末端已被充分表征为蛋白质-蛋白质相互作用。因此,这些研究的长期目标是利用体内小鼠模型来获得对 C 末端蛋白质相互作用的新见解。 p53在白血病和髓母细胞瘤中的作用,以及为这些疾病的靶向治疗提供新方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James J Manfredi其他文献
James J Manfredi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James J Manfredi', 18)}}的其他基金
Cell lineage determinants of p53-driven fate outcomes in vivo
p53驱动的体内命运结果的细胞谱系决定因素
- 批准号:
10316263 - 财政年份:2020
- 资助金额:
$ 41.2万 - 项目类别:
Cell lineage determinants of p53-driven fate outcomes in vivo
p53驱动的体内命运结果的细胞谱系决定因素
- 批准号:
10154750 - 财政年份:2020
- 资助金额:
$ 41.2万 - 项目类别:
Cell lineage determinants of p53-driven fate outcomes in vivo
p53驱动的体内命运结果的细胞谱系决定因素
- 批准号:
10538642 - 财政年份:2020
- 资助金额:
$ 41.2万 - 项目类别:
Role of the p53 C-terminal domain in tissue homeostasis, tumor suppression, and oncogenesis
p53 C 末端结构域在组织稳态、肿瘤抑制和肿瘤发生中的作用
- 批准号:
9195074 - 财政年份:2015
- 资助金额:
$ 41.2万 - 项目类别:
Role of the p53 C-terminal domain in tissue homeostasis, tumor suppression, and oncogenesis
p53 C 末端结构域在组织稳态、肿瘤抑制和肿瘤发生中的作用
- 批准号:
9056104 - 财政年份:2015
- 资助金额:
$ 41.2万 - 项目类别:
相似国自然基金
中性氨基酸转运体SNAT2在血管稳态和重构中的作用及机制
- 批准号:82370423
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
催化不对称自由基反应合成手性α-氨基酸衍生物
- 批准号:22371216
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
BRD9通过表观重塑促进支链氨基酸代谢介导TP53突变型胰腺癌化疗耐药的机制研究
- 批准号:82360519
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
氨基酸转运体SLC7A5诱导食管癌免疫治疗获得性耐药的机制研究
- 批准号:82373410
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
(光)电催化硝酸根和有机酸C-N偶联合成氨基酸
- 批准号:22372162
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Designing safe, potent, and cost-effective small peptide erythropoietin analogs
设计安全、有效且经济有效的小肽促红细胞生成素类似物
- 批准号:
10602271 - 财政年份:2023
- 资助金额:
$ 41.2万 - 项目类别:
Chemotherapy-free cure of hemoglobin disorders through base editing
通过碱基编辑无需化疗即可治愈血红蛋白疾病
- 批准号:
10754114 - 财政年份:2023
- 资助金额:
$ 41.2万 - 项目类别:
Structural Mechanisms of DNA Damage Sensing and Activation of the ATR, Fanconi Anemia, and ATM Checkpoints
DNA 损伤感知和 ATR、范可尼贫血和 ATM 检查点激活的结构机制
- 批准号:
10639156 - 财政年份:2023
- 资助金额:
$ 41.2万 - 项目类别:
A cell model of YARS2-associated childhood-onset mitochondrial disease
YARS2 相关的儿童期发病线粒体疾病的细胞模型
- 批准号:
10575369 - 财政年份:2023
- 资助金额:
$ 41.2万 - 项目类别:
Novel Point-of-Care Device for Urinary Hepcidin to Detect Iron Deficiency in Children and Adolescents
用于检测儿童和青少年缺铁情况的新型尿铁调素护理点设备
- 批准号:
10709598 - 财政年份:2022
- 资助金额:
$ 41.2万 - 项目类别: